FindMyKOL
Clinical trialNCT04943848RecruitingPhase 1Interventional

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

SponsorAnn & Robert H Lurie Children's Hospital of ChicagoEnrollment36Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Children'S Health Orange County (choc)

    Orange, California, United States

    Mariko Sato, MD
    Recruiting
  • Ann and Robert H. Lurie Children'S Hospital of Chicago

    Chicago, Illinois, United States

    Ashley S Plant, MD
    Recruiting
  • Dana-Farber Boston Children'S Cancer and Blood Disorders Center

    Boston, Massachusetts, United States

    Susan Chi, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BalstilimabZalifrelimabRHSC-DIPGVax
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Jan 2022
Primary completion
30 Sept 2026
Completion
30 Sept 2027
Last update posted
17 Mar 2026
Registered enrollment
36
Registry id
NCT04943848
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.